Rosetta, Precision Therapeutics Reach Co-marketing Deal for miRview mets2 Assay
July 24, 2012
Rosetta, Precision Therapeutics Reach Co-marketing Deal for miRview mets2 Assay
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Rosetta Genomics, Prime Health Reach Deal for Coverage of MiRview Mets2 Assay
May 20, 2013 / GenomeWeb Daily News - Rosetta Genomics Terminates Deal with Avatao
July 17, 2012 / GenomeWeb Daily News - After Medicare Nod for CUP Diagnostic, Rosetta Aims to Get Coverage for Other miRNA Tests
May 24, 2012 / Gene Silencing News - Rosetta Genomics' 2012 Revenues Nearly Double
March 25, 2013 / GenomeWeb Daily News - Rosetta Revises Deal with Precision to Co-market miRview mets2
October 17, 2012 / GenomeWeb Daily News